Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.
This document summarises the Life Saving Drugs Program Expert Panel's consideration of BioMarin's application to include cerliponase alfa (Brineura®) on the Life Saving Drugs Program for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
The document contains:
- PBAC consideration
- Consumer input
- LSDP Expert Panel consideration
- Treatment guidelines
- Sponsor’s comment.